BIOMAT Database Logo BIOMAT Database Logo

Urinary fibrin split products in lupus nephritis. Correlation with other parameters of renal disease. 1974

S L Marchesi, and R G Aptekar, and A D Steinberg, and H R Gralnick, and J L Decker

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005337 Fibrin A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot. Antithrombin I
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D005921 Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY. Bright Disease,Kidney Scarring,Glomerulonephritides,Scarring, Kidney
D006386 Hemagglutination Tests Sensitive tests to measure certain antigens, antibodies, or viruses, using their ability to agglutinate certain erythrocytes. (From Stedman, 26th ed) Hemagglutination Test,Test, Hemagglutination,Tests, Hemagglutination
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S L Marchesi, and R G Aptekar, and A D Steinberg, and H R Gralnick, and J L Decker
Urinary fibrin split products in lupus nephritis.
March 1976, The Journal of rheumatology,
S L Marchesi, and R G Aptekar, and A D Steinberg, and H R Gralnick, and J L Decker
Urinary fibrin split products in human renal disease.
May 1971, The Journal of laboratory and clinical medicine,
S L Marchesi, and R G Aptekar, and A D Steinberg, and H R Gralnick, and J L Decker
Split products of fibrin in human renal disease.
May 1969, The American journal of medicine,
S L Marchesi, and R G Aptekar, and A D Steinberg, and H R Gralnick, and J L Decker
Urinary fibrin degradation products in childhood acute nephritis.
October 1977, The New Zealand medical journal,
S L Marchesi, and R G Aptekar, and A D Steinberg, and H R Gralnick, and J L Decker
Lupus nephritis: Urinary NGAL predicts renal flares in lupus nephritis.
May 2010, Nature reviews. Nephrology,
S L Marchesi, and R G Aptekar, and A D Steinberg, and H R Gralnick, and J L Decker
Urinary Angiotensinogen Predicts Renal Disease Activity in Lupus Nephritis.
December 2019, Antioxidants & redox signaling,
S L Marchesi, and R G Aptekar, and A D Steinberg, and H R Gralnick, and J L Decker
Significance of fibrin split products in patients with renal failure.
January 1971, Scandinavian journal of haematology. Supplementum,
S L Marchesi, and R G Aptekar, and A D Steinberg, and H R Gralnick, and J L Decker
Fibrin split products.
September 1973, California medicine,
S L Marchesi, and R G Aptekar, and A D Steinberg, and H R Gralnick, and J L Decker
Radiographic contrast media infusions. Measurement of histamine, complement, and fibrin split products and correlation with clinical parameters.
April 1979, The Journal of allergy and clinical immunology,
S L Marchesi, and R G Aptekar, and A D Steinberg, and H R Gralnick, and J L Decker
Serum and urinary fibrin-fibrinogen degradation products in renal disease.
January 1971, Scandinavian journal of haematology. Supplementum,
Copied contents to your clipboard!